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The rapid spread of the disease caused by the novel SARS-CoV-2 virus has led to the use
of multiple therapeutic agents whose efficacy has not been previously demonstrated. The
objective of this study was to analyze whether there is an association between the use of
azithromycin and the evolution of the pulmonary disease or the time to discharge, in patients
hospitalized with COVID-19.
Methods
This was an observational study on a cohort of 418 patients admitted to three regional hospi-
tals in Catalonia, Spain. As primary outcomes, we studied the evolution of SAFI ratio (oxy-
gen saturation/fraction of inspired oxygen) in the first 48 hours of treatment and the time to
discharge. The results were compared between patients treated and untreated with the
study drug through subcohort analyses matched for multiple clinical and prognostic factors,
as well as through analysis of non-matched subcohorts, using Cox multivariate models
adjusted for prognostic factors.
Results
There were 239 patients treated with azithromycin. Of these, 29 patients treated with azi-
thromycin could be matched with an equivalent number of control patients. In the analysis of
these matched subcohorts, SAFI at 48h had no significant changes associated to the use of
azithromycin, though azithromycin treatment was associated with a longer time to discharge
(10.0 days vs 6.7 days; log rank: p = 0.039). However, in the unmatched cohorts, the
increased hospital stay associated to azithromycin use, was no significant after adjustment
using Multivariate Cox regression models: hazard ratio 1.45 (IC95%: 0.88–2.41; p = 0.150).
This study is limited by its small sample size and its observational nature; despite the strong
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Conclusions
We did not find a clinical benefit associated with the use of azithromycin, in terms of lung
function 48 hours after treatment or length of hospital stay.
Introduction
In December 2019, an epidemic outbreak associated with a novel coronavirus (severe acute
respiratory syndrome coronavirus 2, SARS-CoV-2) was reported in Wuhan (China) with
mainly respiratory clinical manifestations [1]. The extent of the outbreak reached such a mag-
nitude that the WHO declared it a pandemic on March 12, 2020 [2]. Although mortality rates
in those affected (approximately 2% among medically treated patients) [3] seem to be overesti-
mated due to underdiagnosis of affected individuals with mild symptoms, the extent of the
pandemic has caused the search for effective treatments to become a top priority.
Several pharmacological agents have been proposed as potential treatments based on theo-
retical considerations, in vitro studies, or clinical trials conducted in conditions caused by
related viruses [4–6]. However, current evidence has not confirmed the presence or absence of
a benefit of these treatments and even warns of the probable risks or adverse effects associated
with their use. Several randomized clinical trials are underway but have not yet been com-
pleted or have not been reported [7, 8].
Azithromycin has been considered, usually combined with hydroxychloroquine, based on
its in vitro action against other viruses, such as influenza A [9, 10], and its potential immuno-
modulatory and anti-inflammatory action in other respiratory diseases [11–13]. Randomized
clinical trials specifically evaluating the clinical benefit of azithromycin, as an isolated treat-
ment for COVID-19, are in course [14], however, their results have yet not been reported.
From observational studies, at the moment this manuscript is being written, only Rosenberg
et al. [15] and Arshad et al. [16] have reported results on the specific use of azithromycin in
Covid-19 disease. In both studies, among hospitalized patients (n = 1428 and n = 2541, respec-
tively) treated or not with azithromicyn and/or hydroxychloroquine, a benefit on mortality
was not found in the group treated with azithromicyn alone. Other studies have evaluated the
use of azithromycin, though in combination with hydroxychloroquine [17–21]. In a random-
ized, open-label and controlled trial by Cavalcanti et al. (n = 667) [20], a benefit on clinical
severity was not found in the group of hospitalized patients treated with the combination of
hydroxychloroquine plus azithromycin. There are other studies on the combination but with
results that are difficult to interpret because they lacked a comparison group [17, 18, 22] or
because some of the patients assigned to the treated group received only hydroxychloroquine
and not the combination with azithromycin [23, 24].
The absence of an adjusted comparison group in the majority of reported observational
studies is relevant given the well-known confounding of the observational design by factors
that influence the choice or not of a certain treatment. One of the methods used to balance this
has been the propensity score [25], as used in the studies by Magagnoli et al. [19] and Geleris
et al. [24], in which no benefit was found from the use of hydroxychloroquine (with or without
azithromycin) in patients with COVID-19. However, this method is not the most appropriate
when trying to obtain comparison groups that also match at the time, or follow-up time, in
which certain factors appear (e.g., time when a third drug is introduced).
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Therefore, we set out to analyze the relevant clinical parameters under the use of azithromy-
cin in patients hospitalized in our health centers, through comparison of groups using multi-
variate analysis and matching techniques based on brute-force algorithms, which can match
patients by variables that change over time.
Method
This observational study was carried out on a cohort of 418 patients admitted to the hospitals
of the Consorci Sanitari de l’Alt Penedès and Garraf (CSAPG), which includes three regional
hospitals with a total of 275 acute-care beds and which serve a reference population of 247,357
inhabitants from the regions of Alt Penedès and Garraf, Catalonia, Spain.
Data were collected from all patients with a clinical picture compatible with COVID-19
(patients diagnosed of COVID-19 pulmonary disease by their doctors upon admission) seen
between March 12 and May 2, 2020, from the time of admission to discharge or up to a maxi-
mum of 30 days after admission. Real-time reverse transcription polymerase chain reaction
(RT -PCR) for SARS-CoV-2 was performed on a sample obtained by nasopharyngeal smear to
all patients. Patients with negative RT-PCR test were excluded.
The data were collected from the electronic medical records by the COVID-19 research
group of CSAPG. The data collected included sociodemographic data, previous diseases,
chronic treatments, symptoms of disease presentation, vital signs, and clinical evolution each
day since admission, including the need for oxygen therapy, the inspired fraction of oxygen
(FiO2), and the oxygen administration system (nasal prongs, Venturi mask, reservoir mask, or
invasive or noninvasive mechanical ventilation). All treatments given during admission were
recorded, as well as all analyses and chest radiographs performed. The researchers responsible
for data collection collected the data using a structured form created in the OpenClinica, ver-
sion 3.1. (Copyright © OpenClinica LLC and collaborators, Waltham, MA, USA), following a
common procedure on which they were previously trained. Quality controls were established
during the data collection process, and the errors detected were corrected; the responsible
researchers were retrained when necessary.
As exposure variable, treatment with azithromycin was considered. Azithromycin, accord-
ing to the hospital protocol, was prescribed at a dose of 500 mg on the first day (oral or intrave-
nous), followed by 250 mg daily, until completing 5 days of treatment. A patient was
considered exposed to azithromycin if they received at least three doses of the drug. The main
outcome variables for the efficacy analyses were time to discharge and oxygen saturation
(%)/FiO2(%) ratio (SAFI) at 48 hours after the start of treatment [26, 27]. As secondary vari-
ables, SAFI in the first 96 hours after treatment, and mortality were analyzed.
In the statistical analysis, a double strategy was used: 1) analysis of subcohorts paired by
confounding factors and 2) analysis of unpaired subcohorts, adjusted for confounding factors.
As part of the first strategy, a subcohort of patients treated with the study drug was formed,
and a control subcohort was matched with the treatment group (1:1 match ratio). The patients
were matched by the following prognostic markers, which were collected dichotomously (Yes/
No) after detailed reading of all available patient reports: sex, age, obesity, heart failure, chronic
renal failure, and sleep apnea–hypopnea syndrome (SAHS).
The above listed prognostic markers, which were used as matching criteria, were identified
in multivariate binary logistic regression models, in which severe disease (defined as need for
oxygen therapy with a non-rebreathing masks or mechanical ventilation) and death were
taken as dependent variables. The variables introduced in these models were pre-selected from
those pathological antecedents with significant association to the outcomes (bivariate analyses;
p<0.05) by using the Lasso technique [28]. Virtually all the available pathological history of
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the patients was tested: cardiovascular, digestive, osteoarticular, pulmonary, endocrine, neuro-
logical, psychiatric diseases, kidney failure, neoplasms, autoimmune diseases and several
immunodeficiencies (all the diseases within these categories were treated in a dichotomic way:
presence vs absence of the disease).
Follow-up of each patient started the day the patient took the first dose of a study drug. Fol-
low-up of each control started the day after admission on which SAFI, vital signs (blood pres-
sure and heart rate), radiological involvement, and C-reactive protein (CRP), were similar to
those of the patient with whom they were matched. For this purpose, the CRP on day 1 of fol-
low-up of the patient or, failing that, the day before the start of treatment, was taken as refer-
ence. Likewise, the radiological involvement on the treatment started, or any previous time up
to a maximum of two days before the start of treatment, was considered. Missing data on
radiological involvement were imputed in the following way: It was assumed that the radiolog-
ical involvement on the days between two equal radiographs was the same as on the days of
said radiographs (e.g., if a patient had an X-ray with three affected quadrants on day 1 and
another with three affected quadrants on day 6, it was assumed that on all intervening days
they had three affected quadrants). This interpolation was allowed up to a maximum interval
of 6 days between radiographs. No missing data were imputed for other variables. Patients
who received the study treatment and their controls were matched only if they had received
the same other treatments for COVID-19, including hydroxychloroquine, lopinavir/ritonavir,
interferon, corticosteroids, or tocilizumab. A margin of 3 days of lag at the start of the other
treatments was tolerated between the patients under study and the matched controls. In pre-
liminary analyzes, we found no effect of heparin treatment on the results of this study, which is
why this drug was not included among the matching criteria.
For pairing, a first step was performed using brute-force computing algorithms, which
identified all possible controls in the database for each of the patients who received the study
treatment. In this first step, controls were chosen who had the same sex and state of obesity
("yes" vs "no", according to the clinical history), the same radiological involvement (number of
affected quadrants on anteroposterior radiography: 0–4) and an age difference not exceeding
15 years. The control was allowed to have a SAFI from 1.1 points lower to 2 points higher than
the treated patient and a CRP from 6 mg/dL lower to 4 mg/dL higher than the treated patient.
The matching was then refined, choosing from among the previously identified potential con-
trols the most similar in terms of SAFI, blood pressure, heart rate, and CRP by the propensity
score. The complete process of selecting patient pairs, including the procedures performed by
the brute force algorithms, are summarized in Fig 1.
The success of the matching was verified by comparing means or percentages between
groups. A different trend in the evolution of patients (improvement in one group and worsen-
ing in another) was discarded, verifying that the difference between the SAFI was similar
between day 1 of analysis and the day before entering the analysis. In the matched subcohorts,
the SAFI was studied at 48, 72, and 96 hours using Student’s t-test for independent samples
and the time to discharge using the log-rank test. In the SAFI analyses, patients with palliative
sedation were excluded because in these patients SAFI is not related to the severity of the dis-
ease. In the analysis of time to discharge, deceased patients were excluded.
In the analysis of unmatched subcohorts (second analysis strategy), the effect of azithromy-
cin was analyzed in a subcohort in which all patients had been treated with hydroxychloro-
quine and lopinavir/ritonavir, from which patients treated with corticosteroids or other drugs
that were distributed significantly asymmetrically between groups were excluded. In the analy-
sis of these subcohorts, the total length of hospital stay was counted from day 1 of admission,
and patients were considered exposed to the study drug if they had taken it at any time since
admission (at least three doses). The time to discharge (excluding deceased patients) and
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mortality were studied by fitting Cox regression models adjusted for the following covariates:
sex, age, obesity, heart failure, chronic renal failure, SAHS, baseline saturation in the emer-
gency room, CRP in the emergency room, and quadrants affected in the emergency
radiography.
For the statistical analysis, R software version 3.6.1 (R Project for Statistical Computing)
and IBM SPSS statistics version 26 were used.
The research ethics committee Bellvitge Hospital reviewed the study and accepted the
waiver of the patient’s informed consent, as it was an observational and ambispective review of
clinical data, and the patient’s personal data were anonymized for its publication. Approval
from the Ethical Committee was granted before starting data collection.
Results
Of the 464 consecutive patients with a clinical diagnosis of COVID-19 and pulmonary involve-
ment who were admitted between March 12 and May 2, 2020, 46 were excluded for having a
negative RT-PCR for SARS-CoV-2. Of the 418 patients included in the analysis, 238 (56.9%)
were men and 180 (43.1%) were women, the mean age of the sample was 65.4 years (SD 16.6
years), and the median follow-up was 8 days (IQR 5–12 days). In total, 239 (57.2%) patients
were treated with azithromycin. Patients who were treated with both hydroxychloroquine and
lopinavir/ritonavir during admission totaled 346 (82.8%). In the first 30 days after admission,
79 patients died (18.9%). Fig 2 shows a flow diagram of the sample of the study.
The characteristics of the matched subcohorts are shown in Table 1. Comparing to the
source cohort, matched cohorts had a larger proportion of men, and included patients with
better respiratory function (higher saturation and less chest-x-ray involvement) as can be seen
in Table 2. The characteristics of the unmatched subcohorts are shown in Table 3. Table 4
shows the mean change in saturation, FiO2 and SAFI, with respect to baseline, after 48, 72, and
96 hours of treatment, in the matched subcohorts. In the analysis of matched cohorts, hospital
satay was significantly longer in patients treated with azithromycin, compared with their
paired controls (Logrank; p = 0.039). However, in the unmatched cohorts, the increased hospi-
tal stay associated to azithromycin use, was no significant after adjustment using Multivariate
Fig 1. Process of selection of matched controls.
https://doi.org/10.1371/journal.pone.0238681.g001
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Cox regression models: hazard ratio 1.45 (IC95%: 0.88–2.41; p = 0.150). Fig 3 shows the unad-
justed Kaplan-Meier comparison curves and log-rank test for the time to discharge in all stud-
ied subcohorts.
Six deaths (8.1%) were recorded in the unmatched control subcohort (treated with hydro-
xychloroquine and lopinavir/ritonavir) and 7 people (5.3%) died in the subcohort receiving
additional treatment with azithromycin (p = 0.501). In the matched subcohorts 3 people died,
1 of them (3.4%) in the azithromycin group, and 2 (6.9%) in the control group. We considered
this numbers of events insufficient to draw conclusions.
Discussion
Our study did not find a benefit associated with the use of azithromycin in terms of respiratory
function (SAFI), or time to discharge. In fact, hospital stay was longer in the azithromycin
treated group, compared with matched controls.
Most of the patients in our study received hydroxychloroquine and lopinavir/ritonavir,
therefore our results are mainly related to the potential benefit of adding azithromycin to this
Fig 2. Flow diagram.
https://doi.org/10.1371/journal.pone.0238681.g002
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drug regimen. Our results are in line with the work by Cavalcanty et al. [20] who found no
benefit on clinical severity in the group of patients receiving hydroxychloroquine plus azithro-
mycin compared to the group who received only hydroxychloroquine. Rosenberg et al. [15]
and Arshad et al. [16] investigated similar patients in terms of setting (hospitalized patients),
severity (moderate or severe disease) and oxygenation parameters and found no benefit on
hospital mortality in the group of patients treated with azithromycin alone.
Our sample included only hospitalized patients, so our results should be considered in the
realm of hospital management of COVID-19 and cannot be extrapolated to patients with mild
symptoms in whom outpatient treatment and monitoring is usually recommended. In




Age (years) 63.0 63.1 0.987
Men (n,%) 21 (72.4%) 21 (72.4%) 1.000
Obesity (n) 3 (10.3%) 3 (10.3%) 1.000
CHF (n) 1 (3.5%) 1 (3.5%) 1.000
CRF (n) 2 (6.7%) 5 (17.2%) 0.423
SAHS (n) 3 (10.3%) 3 (10.3%) 1.000
Tobacco (n) 1 (3.4%) 3 (10.3%) 0.611
Hypertension (n) 12 (41.4%) 11 (37.9%) 1.000
Diabetes (n) 5 (20.7%) 6 (17.2%) 1.000
COPD (n) 1 (3.4%) 1 (3.4%) 1.000
Other cardiopathy (n) 5 (17.2%) 2 (6.9%) 0.433
Saturation (%) 96.1 96.4 0.521
Systolic BP (mmHg) 121.6 123.4 0.690
Diastolic BP (mmHg) 70.7 68.7 0.484
HR (bpm) 77.8 78.5 0.783
Temperature (˚C) 36.7 36.6 0.686
SAFI1 3.6 3.5 0.668
SAFI trend2 0.0 0.0 0.983
Radiographic involvement3 1.5 1.5 0.632
CRP (mg/dL) 7.4 8.0 0.655
Urea (mg/dL) 41.3 (n23)� 37.7 (n19)� 0.649
Neutrophils (10e9/L) 4.3 (n25)� 5.4 (n6)� 0.302
Lymphocytes (10e9/L) 1.1 (n25)� 1.0 (n6)� 0.511
Hydroxychloroquine (n) 27.0 26.0 0.640
Lop/Rit (n) 27.0 26.0 0.640
Interferon (n) 3 4 0.687
Tocilizumab (n) 5 3 0.706
Methylprednisolone (n) 1 0 0.313
Dexamethasone (n) 8 7 0.764
Hospital stay (days) 10.0 6.7 0.025
CHF: congestive heart failure. CRF: chronic renal failure. SAHS: sleep apnea–hypopnea syndrome. BP: blood pressure. HR: heart rate. SAFI: saturation (%)/fraction of
inspired O2 (%). CRP: C-reactive protein.
1 Maximum value 4.76, corresponding to 100% saturation with FiO2 of 21%.
2 Change in SAFI with respect to the day before the start of the follow-up period.
3 Number of affected quadrants in an anteroposterior chest radiograph. Range: 0–4 (0: no involvement; 4: involvement of the upper and lower lobes of both lungs).
� Information not available for all the patients.
https://doi.org/10.1371/journal.pone.0238681.t001
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addition, matching criteria cause patient selection, so that only those patients for whom a pair
is found, enter the analysis (possibly selecting the most frequent type of patient). This means
that the selected subcohorts do not represent well the total hospital population with COVID-
19 and the results of this study are only applicable to patients with features similar to ours.
Given the observational nature of this study, the existence of residual confounders cannot
be ruled out, thus, a possibility exists that patients assigned to azithromycin treatment would
have a higher-risk factors or disease severity. In the case of azithromycin, we believe that this
problem is not likely since its use was widespread and not related to the severity of the disease.
In any event, the exhaustive matching method used and the verification of the comparability
of the groups lead us to assume that this confounding effect was unlikely and, if there, was
small. Some factors could affect hospital discharge beyond the resolution of the infection, such
as the presence of complications or factors related to social circumstances, especially in elderly
patients (which could have prevented them from returning home). Since all the patients in the
sample were admitted for COVID-19, the complications derived from hospitalization for this
disease, seem to us to be part of the clinical picture we are studying and, therefore, their influ-
ence in the outcome seems appropriate. Regarding social factors affecting discharge, we think
that the age matching of the paired subcohorts, should have mitigated its possible influence in
the results. In any event, the most important confounder that could have affected the time to
discharge is death, which was appropriately controlled, by excluding the deceased patients
from this analysis.
The worse respiratory function at 72 hours of treatment, observed in azithromycin matched
subcohort, may be affected by a selection bias, as there was a loss of data in four matched con-
trols at the time of this comparison, which was a secondary endpoint (loss of patients may
have unbalance the previously matched groups).
Table 2. Comparison between matched subcohorts and source cohort.
Total cohort (n 418) Matched subcohorts (n 58) p
Age 65,4 63.1 0.320
Men 238 (57,1%) 42 (72.4%) 0.032
Obesity 74 (17.7%) 6 (10.3%) 0.192
CHF 26 (6,2%) 2 (3,4%) 0.558
CRF 61 (14,6%) 7 (12,1%) 0.693
SAHS 34 (8,1%) 6 (10,3%) 0.611
Tobacco 36 (8,6%) 4 (6,9%) 0,804
Hypertension 217 (51,9%) 23 (39.7%) 0.093
Diabetes 99 (23,7%) 11 (19.0%) 0,268
COPD 41 (9.8%) 2 (3.4%) 0.143
Other cardiopathy 62 (14.8%) 7 (12.1%) 0.693
Saturation 91,6 93.9 0.031
Radiographic involvement 1 2,07 1,59 0,003
CRP (mg/dL) 12.4 (n156)� 9.8 0,231
Urea (mg/dL) 48.0 (n337)� 38.3 (n42)� 0.088
Neutrophils (10e9/L) 6.0 4.7 0.015
Lymphocytes (10e9/L) 1.1 1.1 0.654
Hospital stay 9.3 9.2 0.775
� Information is not available for all the patients.
1 Number of affected quadrants in an anteroposterior chest radiograph. Range: 0–4 (0: no involvement; 4: involvement of the upper and lower lobes of both lungs).
https://doi.org/10.1371/journal.pone.0238681.t002
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Table 3. Baseline characteristics of the subcohorts of patients treated with hydroxychloroquine/lopinavir-ritonavir and patients with additional treatment with azi-
thromycin (un-matched subcohorts).
HCL/LOP (n 63) HCL/LOP/AZT (n 120) p
Age 57.2 61.6 0.066
Men 35 (52.2%) 57 (47.5%) 0.534
Obesity 12 (17.6%) 17 (14.2%) 0.526
CHF 3 (4.4%) 7 (5.8%) 1.000
CRF 4 (5.9%) 14 (11.7%) 0.195
SAHS 5 (7.4%) 10 (8.3%) 0.812
Tobacco 3 (4.4%) 17 (14.2%) 0,028
Hypertension 24 (35.3%) 57 (47.5%) 0.126
Diabetes 11 (16.2%) 25 (20.8%) 0,563
COPD 1 (1.5%) 7 (5.8%) 0,262
Other cardiopathy 9 (13,2%) 16 (13.3%) 1.000
Saturation 93.7 94.4 0.301
Radiographic involvement 1 2.13 1.68 0.004
CRP (mg/dL) 9.9 (n26)� 8.2 (n33)� 0.295
Urea (mg/dL) 33.2 (n 38)� 37.6 (n 111)� 0.440
Neutrophils (10e9/L) 5.1 (n38)� 5.0 (n115)� 0.942
Lymphocytes (10e9/L) 1.2 (n38)� 1.2 (n115)� 0.732
Hydroxychloroquine 63 (100%) 120 (100%) -
Lop/Rit 63 (100%) 120 (100%) -
Interferon 12 (17.6%) 12 (10.0%) 0.131
Tocilizumab 7 (10.3%) 11 (9.2%) 0.801
Methylprednisolone 0 0 -
Dexamethasone 0 0 -
Hospital stay (days) 5.7 8.5 <0.001
AZT: Azithromycin. CHF: congestive heart failure. CRF: chronic renal failure. CRP: C-reactive protein. HCQ: hydroxychloroquine. L/R: lopinavir/ritonavir. SAHS:
sleep apnea-hypopnea syndrome.
1 Number of affected quadrants in an anteroposterior chest radiograph. Range: 0–4 (0: no involvement; 4: involvement of the upper and lower lobes of both lungs).
� Information not available for all the patients.
https://doi.org/10.1371/journal.pone.0238681.t003
Table 4. Change in respiratory function parameters with respect to the first day of follow-up in patients treated with azithromycin.
Azithromycin Control Mean difference (IC95%) p
Saturation increment
48 hours -0.82 (n29) -0.81 (n29) 0.02 (-1.35; 1.39) 0.980
72 hours -0.58 (n29) -0.43 (n25) 0.15 (-1.18; 1.48) 0.821
96 hours -0.91 (n27) -0.40 (n24) 0.51 (-0.72; 1.74) 0.411
FiO2 increment
48 hours 4.93 (n29) 3.33 (n29) -1.60 (-11.36;8.16) 0.744
72 hours 9.07 (n29) 0.56 (n27) -8.51 (-21.77; 4.75) 0.203
96 hours 6.65 (n27) -5.45 (n23) -12.10 (-23.70; -0.50) 0.041
SAFI increment
48 hours -0.19 (n29) -0.01 (n29) 0.19 (-0.26; 0.64) 0.408
72 hours -0.23 (n29) 0.34 (n25) 0.57 (0.01; 1.14) 0.046
96 hours -0.08 (n27) 0.40 (n23) 0.49 (-0.08; 1.05) 0.074
FiO2: fraction of inspired oxygen.
https://doi.org/10.1371/journal.pone.0238681.t004
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Our study was limited by its small sample size, which caused problems of statistical power,
especially in the case of some of the outcomes of greatest interest, such as mortality, which can-
not be sufficiently studied in this sample. In addition, the use of secondary data obtained from
the clinical history might have led to information biases. However, given that the main vari-
ables were quantitative parameters that were little influenced by the observers or their expertise
in measurement, and given that these parameters are routinely collected in clinical practice
and hospital management, we consider unlikely the existence of a relevant bias of this type. In
any case, the sample size and observational nature of our study make it necessary to wait for
the results of randomized clinical trials, which are ongoing, to confirm ours.
In conclusion, in this observational study, we did not find evidence of a clinical benefit
from the use of azithromycin in patients hospitalized with COVID-19. The use of azithromy-
cin may be associated with worse clinical results, compared with matched controls.
Fig 3. Kaplan-Meier comparison curves and log-rank test outcomes of the different subcohorts (unadjusted).
https://doi.org/10.1371/journal.pone.0238681.g003
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